Calidi Biotherapeutics, Inc.
ASE: CLDILive Quote
📈 ZcoreAI Score
Our AI model analyzes Calidi Biotherapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CLDI Z-Score →About Calidi Biotherapeutics, Inc.
Healthcare
Biotechnology
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Calidi Biotherapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -700.6%, which indicates that capital utilization is currently under pressure.
At a current price of $0.26, CLDI currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $0.21 - $19.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$2.79M
Trailing P/E
--
Forward P/E
-0.29
Beta (5Y)
1.42
52W High
$19.20
52W Low
$0.21
Avg Volume
286K
Day High
Day Low